StreetInsider.com News Articles

SkinHealth Systems to Report Second Quarter 2026 Financial Results on August 6, 2026

Tue, 21 Jul 2026 10:00:00 -0400

LONG BEACH, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- SkinHealth Systems Inc. (NASDAQ: SKIN), a global medical aesthetics company and home to flagship brand Hydrafacial, today announced it will report second quarter 2026 financial results after market close on Thursday, August 6, 2026. The Company will host an investor conference call at 4:30 p.m. Eastern Time, following a press release detailing the results.

A live webcast of the call can be accessed on the investor relations section of the Company’s website at www.skinhealthsystems.com, along with supporting materials. A recording of the

SkinHealth Systems to Report Second Quarter 2026 Financial Results on August 6, 2026

Tue, 21 Jul 2026 10:00:00 -0400

A live webcast of the call can be accessed on the investor relations section of the Company’s website at www.skinhealthsystems.com, along with supporting materials. A recording of the

SkinHealth Systems to Report Second Quarter 2026 Financial Results on August 6, 2026

Tue, 21 Jul 2026 10:00:00 -0400

A live webcast of the call can be accessed on the investor relations section of the Company’s website at www.skinhealthsystems.com, along with supporting materials. A recording of the

SkinHealth Systems to Report Second Quarter 2026 Financial Results on August 6, 2026

Tue, 21 Jul 2026 10:00:00 -0400

A live webcast of the call can be accessed on the investor relations section of the Company’s website at www.skinhealthsystems.com, along with supporting materials. A recording of the

Form SCHEDULE 13G SkinHealth Systems Inc. Filed by: BlackRock Portfolio Management LLC

Fri, 17 Jul 2026 11:33:00 -0400

si-local-file:///var/storage/secattach/20260717/26783066.html

Form SCHEDULE 13G SkinHealth Systems Inc. Filed by: BlackRock Portfolio Management LLC

Fri, 17 Jul 2026 11:33:00 -0400

si-local-file:///var/storage/secattach/20260717/26783066.html

Form SCHEDULE 13G/A SkinHealth Systems Inc. Filed by: Capricorn Fund Managers Ltd

Mon, 13 Jul 2026 07:17:00 -0400

si-local-file:///var/storage/secattach/20260713/26759701.html

Form SCHEDULE 13G/A SkinHealth Systems Inc. Filed by: Capricorn Fund Managers Ltd

Mon, 13 Jul 2026 07:17:00 -0400

si-local-file:///var/storage/secattach/20260713/26759701.html

Form SCHEDULE 13G/A SkinHealth Systems Inc. Filed by: FMR LLC

Wed, 08 Jul 2026 10:12:00 -0400

si-local-file:///var/storage/secattach/20260708/26745702.html

Form SCHEDULE 13G/A SkinHealth Systems Inc. Filed by: FMR LLC

Wed, 08 Jul 2026 10:12:00 -0400

si-local-file:///var/storage/secattach/20260708/26745702.html

SkinStylus gets FDA clearance for periorbital wrinkles across skin types

Tue, 07 Jul 2026 08:06:08 -0400

SkinHealth Systems Inc. (NASDAQ: SKIN) announced that the U.S. Food and Drug Administration has cleared its SkinStylus microneedling device for the improvement of periorbital wrinkles in adults aged 22 and older across all Fitzpatrick skin types (I–VI).

The SkinStylus SteriLock MicroSystem, classified by the FDA as a Class II medical device, now carries three FDA-cleared indications: improvement in the appearance of periorbital wrinkles, including crow's feet; improvement in the appearance of facial acne scars in Fitzpatrick skin types I, II, and III; and improvement in the appearance of surgical or traumatic hypertrophic scars on the abdomen.

Whitney Cypes, Chief Brand and Clinical

SkinStylus gets FDA clearance for periorbital wrinkles across skin types

Tue, 07 Jul 2026 08:06:08 -0400

Whitney Cypes, Chief Brand and Clinical

SkinStylus® Receives New FDA Clearance for the Improvement of Periorbital Wrinkles for All Skin Types

Tue, 07 Jul 2026 08:05:00 -0400

SkinStylus SteriLock MicroSystem Now the Only Microneedling Device with Indications for Facial Acne Scars, Periorbital Wrinkles, and Abdominal Scars

Hydrafacial Treatment Pairing Continues to Drive Adoption of Microneedling Protocols

LONG BEACH, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- SkinHealth Systems Inc. (NASDAQ: SKIN), home to flagship brand Hydrafacial, today announced that the U.S. Food and Drug Administration (FDA) has cleared the SkinStylus microneedling device for the improvement of the appearance of periorbital wrinkles in adults aged 22 years and older for all Fitzpatrick skin types.

This latest clearance expands SkinStylus’ clinically supported indications

SkinStylus® Receives New FDA Clearance for the Improvement of Periorbital Wrinkles for All Skin Types

Tue, 07 Jul 2026 08:05:00 -0400

SkinStylus SteriLock MicroSystem Now the Only Microneedling Device with Indications for Facial Acne Scars, Periorbital Wrinkles, and Abdominal Scars

Hydrafacial Treatment Pairing Continues to Drive Adoption of Microneedling Protocols

This latest clearance expands SkinStylus’ clinically supported indications

SkinStylus® Receives New FDA Clearance for the Improvement of Periorbital Wrinkles for All Skin Types

Tue, 07 Jul 2026 08:05:00 -0400

SkinStylus SteriLock MicroSystem Now the Only Microneedling Device with Indications for Facial Acne Scars, Periorbital Wrinkles, and Abdominal Scars

Hydrafacial Treatment Pairing Continues to Drive Adoption of Microneedling Protocols

This latest clearance expands SkinStylus’ clinically supported indications

SkinStylus® Receives New FDA Clearance for the Improvement of Periorbital Wrinkles for All Skin Types

Tue, 07 Jul 2026 08:05:00 -0400

SkinStylus SteriLock MicroSystem Now the Only Microneedling Device with Indications for Facial Acne Scars, Periorbital Wrinkles, and Abdominal Scars

Hydrafacial Treatment Pairing Continues to Drive Adoption of Microneedling Protocols

This latest clearance expands SkinStylus’ clinically supported indications

AbbVie and Galderma Control 80% of Aesthetic Medicine's AI Citations, New 5W Index Finds